SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+36.98%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$290M
AUM Growth
+$290M
(+23%)
Cap. Flow
+$29.5M
Cap. Flow
% of AUM
10.15%
Top 10 Holdings %
Top 10 Hldgs %
36.73%
Holding
98
New
24
Increased
37
Reduced
19
Closed
12
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$14.5M |
| 2 |
Nuvalent
NUVL
|
$7.79M |
| 3 |
Terns Pharmaceuticals
TERN
|
$6.98M |
| 4 |
Biogen
BIIB
|
$6.09M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$5.5M |
Top Sells
| 1 |
Veracyte
VCYT
|
$11.1M |
| 2 |
Akero Therapeutics
AKRO
|
$7.01M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$6.26M |
| 4 |
Cogent Biosciences
COGT
|
$4.94M |
| 5 |
Nkarta
NKTX
|
$4.77M |
Sector Composition
| 1 | Healthcare | 96.19% |
| 2 | Technology | 0.09% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gilead Sciences
GILD
$140B
| $4.46M | 1.28% | +51,962 | New | +$4.46M |
|
27
Prothena Corp
PRTA
$441M
| $4.32M | 1.24% | 71,706 -38,294 | -35% | -$2.31M |
|
28
Merus
MRUS
$4.98B
| $4.25M | 1.22% | 274,704 -20,432 | -7% | -$316K |
|
29
Pliant Therapeutics
PLRX
$101M
| $4.2M | 1.2% | 217,503 +7,681 | +4% | +$148K |
|
30
MacroGenics
MGNX
$112M
| $4.11M | 1.18% | 612,475 +512,475 | +512% | +$3.44M |
|
|
ALLK
31
DELISTED
Allakos
ALLK
| $4.05M | 1.16% | 480,701 +80,701 | +20% | +$680K |
|
32
Vaxcyte
PCVX
$4B
| $3.99M | 1.14% | +83,135 | New | +$3.99M |
|
33
Immatics
IMTX
$619M
| $3.83M | 1.1% | 439,788 +275,850 | +168% | +$2.4M |
|
34
Vertex Pharmaceuticals
VRTX
$100B
| $3.29M | 0.94% | 11,384 +279 | +3% | +$80.6K |
|
35
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.12M | 0.89% | 272,173 +85,570 | +46% | +$982K |
|
|
PNT
36
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $2.92M | 0.84% | 400,812 +100,812 | +34% | +$735K |
|
37
Avidity Biosciences
RNA
$5.99B
| $2.84M | 0.81% | +128,000 | New | +$2.84M |
|
38
Ascendis Pharma
ASND
$11.8B
| $2.83M | 0.81% | 23,151 +18,151 | +363% | +$2.22M |
|
39
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.8M | 0.8% | 152,747 +3,720 | +2% | +$68.1K |
|
40
Phreesia
PHR
$1.88B
| $2.76M | 0.79% | 85,390 +2,085 | +3% | +$67.5K |
|
|
HZNP
41
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.62M | 0.75% | 23,054 +12,923 | +128% | +$1.47M |
|
42
Insmed
INSM
$28.8B
| $2.49M | 0.71% | 124,465 -99,551 | -44% | -$1.99M |
|
43
Celldex Therapeutics
CLDX
$1.47B
| $2.44M | 0.7% | 54,699 +1,424 | +3% | +$63.5K |
|
44
Cullinan Oncology
CGEM
$445M
| $2.42M | 0.69% | 229,416 +4,861 | +2% | +$51.3K |
|
45
Seres Therapeutics
MCRB
$166M
| $2.1M | 0.6% | 374,422 +7,929 | +2% | +$44.4K |
|
|
46
Cogent Biosciences
COGT
$1.69B
| $2.07M | 0.59% | 179,000 -427,608 | -70% | -$4.94M |
|
|
IMGN
47
DELISTED
Immunogen Inc
IMGN
| $2.02M | 0.58% | 407,269 -31,426 | -7% | -$156K |
|
48
Schrodinger
SDGR
$1.44B
| $2.02M | 0.58% | +108,000 | New | +$2.02M |
|
|
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.89M | 0.54% | 88,243 -89,121 | -50% | -$1.91M |
|
50
Acumen Pharmaceuticals
ABOS
$82.4M
| $1.59M | 0.46% | 295,115 -124,885 | -30% | -$674K |
|